Drug intelligence / Profile preview

methotrexate + sinomenine

Development stage: Preclinical
Lead developer: Pfizer
Modality: Small Molecules
Administration: Oral

Overview

A combination therapy consisting of methotrexate (MTX) and sinomenine (SIN). This combination has shown additive effects in decreasing inflammation and joint damage in rheumatoid arthritis by modulating osteoclast-related cytokines. Sinomenine, extracted from CAULIS SINOMENII, alleviates morning stiffness and joint pain by inhibiting various inflammatory mediators and pathways, including cyclooxygenase 2, TNF, IL-6, and NF-κB. It also regulates immunity by inhibiting T-lymphocyte and B-lymphocyte activation.

Targets

DHFR (Dihydrofolate reductase)GBP5 (Guanylate-binding protein 5)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)

Beyond the preview

Go deeper on methotrexate + sinomenine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on methotrexate + sinomenine.

Explore the full profile